Jeffrey W. Albers, Director at Spyre Therapeutics, Inc. (SYRE), sold 23,000 shares at $104.47 ($2.4M) on 2026-08-07, disclosed to the SEC on 2026-08-10.
Scheduled sale ($2.4M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $104.38 | 8,000 | $835K | 34.7% |
| 2 | $104.47 | 5,000 | $522K | 21.7% |
| 3 | $104.68 | 10,000 | $1.0M | 43.5% |
| Total | $104.53 avg | 23,000 | $2.4M | 100% |
| Filing → |
| KYMR | SELL | 2025-06-03 | $311K | — | Filing → |
| BPMC | SELL | 2025-05-29 | $572K | — | Filing → |
| BPMC | SELL | 2025-03-17 | $1.0M | — | Filing → |